Draft GuidancecriticalComment deadline: March 31, 2025
FDA Publishes Draft Guidance on Cannabidiol in Dietary Supplements: Conditions for Regulatory Discretion
Agency signals limited enforcement for qualifying low-dose CBD products while legislative pathway remains open
Announced: January 28, 2025
FDA Docket: FDA-2025-D-0445
Federal Register: 90 Fed. Reg. 8921
CBDDietary Supplement
Summary
In a significant development, FDA published draft guidance in January 2025 outlining conditions under which the agency intends to exercise "regulatory discretion" and refrain from enforcement action against dietary supplements containing CBD. The draft guidance (FDA-2025-D-0445) does not legalize CBD supplements — it establishes a safe harbor from FDA enforcement for products meeting specific criteria.
Conditions for regulatory discretion:
- CBD content not to exceed 30 mg per daily serving
- No disease claims; only permissible structure/function claims with DSHEA disclaimer
- No marketing to children or pregnant/breastfeeding women
- Product not marketed in combination with alcohol or other intoxicants
- Manufacturer maintains GMP compliance and batch testing records
- Adverse event reporting per 21 C.F.R. Part 111
- No additives on FDA's list of substances raising safety concerns
This draft guidance represents the most important regulatory development for the CBD supplement industry since the 2018 Farm Bill. The comment deadline is March 31, 2025.
Deep-Dive Analysis
🔒
Federal Pulse-Plus Exclusive
Full analysis is available to Federal Pulse-Plus subscribers ($499/mo). Includes in-depth regulatory breakdown, risk assessment, and Bob Hoban's strategic recommendations.
What Operators Should Do Now
The most important regulatory comment deadline in CBD history — March 31, 2025:
1. Submit a comment to FDA-2025-D-0445 before March 31 — this is the single highest-leverage action a CBD supplement company can take in 2025.
2. Audit your product formulations against the six criteria: ≤30 mg/day, no disease claims, no child marketing, no alcohol combinations, GMP compliance, and no listed additives.
3. Implement or verify GMP documentation — the guidance makes this a prerequisite, not an aspiration.
4. Establish an adverse event reporting program under 21 C.F.R. Part 111 if you don't already have one.
5. Consult M&A and investment counsel — the draft guidance materially improves the regulatory risk profile of compliant CBD supplement businesses for acquisition financing purposes.